Xenon Pharmaceuticals XENE Unveils Robust Azetukalner Phase III Data Q3 NDA Filing Plans at Bloom Burton Conference Exponent EXPO Stock Is It Testing Key Levels Steady Decline 20260427 What idiosyncratic risk Exodus Movement EXOD Investor Concern 20260427